Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.51 |
| ▸ | PDE1A | P54750 | 2/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.50 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.50 |
| ▸ | PDE6C | P51160 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018906 | 0.89 | PDE5A (0.59) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL3023422 | 0.89 | PDE5A (0.54) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL3012296 | 0.84 | PDE5A (0.55) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL3030666 | 0.83 | PDE5A (0.55) | PDE5APDE6C | |
| SCHEMBL3023423 | 0.81 | PDE5A (0.63) | PDE5APDE1APDE1BPDE1C | |
| SCHEMBL3029660 | 0.81 | PDE5A (0.64) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL3019452 | 0.80 | PDE5A (0.65) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL3017892 | 0.80 | PDE5A (0.65) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL3026577 | 0.79 | PDE5A (0.74) | PDE5APDE1APDE1BPDE1CPDE6C | |
| SCHEMBL3023652 | 0.78 | PDE5A (0.55) | PDE5APDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461165-B2 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD (CN) | 2013-06-11 | — | — | US | disclosed |
| EP-1634883-B1 | 2-SUBSTITUTED PHENYL-5,7-DIALKYL-3,7-DIHYDROPYRROLE[2,3-D] PYRIMIDINE-4-ONE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL G (CN) | 2010-12-15 | — | — | EP | disclosed |
| US-20100204223-A1 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2010-08-12 | — | — | US | disclosed |
| US-7745433-B2 | 2-Substituted phenyl-5, 7-dihydrocarbyl-3, 7-dihydropyrrolo [2, 3-D] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | Yangtze River Pharmacuetical (Group) Co., Ltd. (CN) | 2010-06-29 | — | — | US | disclosed |
| US-7741483-B2 | Process for making substituted pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of phosphodiesterase 5 | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2010-06-22 | — | — | US | disclosed |
| US-20080167462-A1 | 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | TIANJIN TASLY GROUP CO., LTD (CN) | 2008-07-10 | — | — | US | disclosed |
| US-20060173025-A1 | 2-Substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole [2,3-d]pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof | YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2006-08-03 | — | — | US | disclosed |
| EP-1634883-A1 | 2-SUBSTITUTED PHENYL-5,7-DIALKYL-3,7-DIHYDROPYRROLE[2,3-D]PYRIMIDINE-4-ONE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF | Tianjin Tasly Group Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167462-A1 | 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3B, PDE2A | PDE5A 1/4885PDE1A 28/4885PDE1B 27/4885 |
| US-20060173025-A1 | 2-Substituted phenyl-5,7-dialkyl-3,7-dihydropyrrole [2,3-d]pyrimidine-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3B, PDE2A | PDE5A 1/4885PDE1A 37/4885PDE1B 24/4885 |
| US-20100204223-A1 | 2-Substituted phenyl-5,7-dihydrocarbyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE1A 23/4885PDE1B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.